Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Non-Current Debt: 2019-2025

Historic Non-Current Debt for China SXT Pharmaceuticals (SXTC) over the last 6 years, with Mar 2025 value amounting to $96,264.

  • China SXT Pharmaceuticals' Non-Current Debt fell 1.63% to $98,126 in Q3 2025 from the same period last year, while for Sep 2025 it was $98,126, marking a year-over-year decrease of 1.63%. This contributed to the annual value of $96,264 for FY2025, which is 17.81% down from last year.
  • As of FY2025, China SXT Pharmaceuticals' Non-Current Debt stood at $96,264, which was down 17.81% from $117,129 recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Non-Current Debt ranged from a high of $117,862 in FY2023 and a low of $6,292 during FY2021.
  • For the 3-year period, China SXT Pharmaceuticals' Non-Current Debt averaged around $110,418, with its median value being $117,129 (2024).
  • Data for China SXT Pharmaceuticals' Non-Current Debt shows a maximum YoY crashed of 82.77% (in 2021) over the last 5 years.
  • Yearly analysis of 4 years shows China SXT Pharmaceuticals' Non-Current Debt stood at $6,292 in 2021, then reached $117,862 in 2023, then decreased by 0.62% to $117,129 in 2024, then declined by 17.81% to $96,264 in 2025.